AI assistant
HOLISTA COLLTECH LIMITED — Capital/Financing Update 2009
Apr 16, 2009
65044_rns_2009-04-16_a5a1d07c-0e08-4e89-9842-0998c3d48ad5.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX/MEDIA RELEASE
17 April 2009
==> picture [151 x 53] intentionally omitted <==
Holista Biotech Sdn Bhd
In announcements dated 3 December 2008 and 17 March 2009, CollTech Australia Limited announced details of the proposed acquisition of Holista Biotech Sdn Bhd (“Holista”). Documentation to finalise this transaction and seek requisite shareholder approvals will be issued shortly.
An article from Business Times, Malaysia concerning Holista has been brought to our attention and is set out below:
Herbal venture brewing
Business Times, 13 April 2009
PEPSICO, a global beverage giant, is working on a drink based on a Malaysian herb that may be sold in Asia, the US and Europe.
The drink would be a major breakthrough for the queen of Malaysian herbs, kacip fatimah, and the local firm that filed two global patents on the herb in 2007 - Holista Biotech Sdn Bhd.
"The drink is slotted for the Malaysian and regional market, and possibly North America and Europe. This is only likely to happen next year though and not this year," Holista Biotech chief executive officer Datuk Dr Rajen M told Business Times in Kuala Lumpur last Friday.
The drink is at the development stage now.
"The kacip fatimah is under testing as part of Pepsi's global research and development programme," Rajen said.
Holista filed patents on the herb's ability to protect the liver and improve the body's immune system.
Rajen said Holista is currently working on another three patents on the herb, and PepsiCo is also interested in one of them.
"At this stage, they are a big company, we are a small one ... for us this deal is very important but for them it is just one of many. Because of this I'd rather engage them on one product at a time, develop it further and get them excited," Rajen said.
Holista Biotech is already a supplier of kacip fatimah or labisia pumila to Nestle for its Nescafe coffee. The product is now sold only in Malaysia.
Holista Biotech is a company under Malaysian Biotechnology Corp's bionexus programme.
So far, it has received some RM3 million in grants from the government, through Malaysian Biotech Corp and Malaysian Technology Development Corp.
Last year, Holista Biotech made RM3 million in profits on revenue of RM15 million. As a bionexus status company, Holista Biotech is exempted from taxes.
"There are no two ways about it. Government incentives help, and tax incentives and exemptions are better than grants because they don't pick the winners, but rewards them," Rajen said.
CollTech Australia Ltd | ABN 24 094 515 992 PO Box 1661 Osborne Park WA 6916 Australia P +618 9426 3900 | F +618 9426 3909 | W www.colltech.com.au | E [email protected]
ASX/MEDIA RELEASE
==> picture [151 x 53] intentionally omitted <==
On April 2, Holista Biotech entered into an agreement with Australian company Colltech Australia Ltd, to take control of the company through a reverse takeover.
Colltech is listed on the Australian Securities Exchange.
Ends
==> picture [127 x 113] intentionally omitted <==
Alan Boys Company Secretary CollTech Australia Limited
About CollTech
CollTech Australia Limited is an ASX‐listed (ASX: CAU) bio‐industrial company based in Perth, Western Australia. CollTech specialises in the development and commercialisation of ovine collagen products and is currently the only company in the world manufacturing and marketing this type of collagen. CollTech’s OVICOLL® ovine collagen has several advantages over its bovine, porcine, ‘plant’ and marine competitors including:
-
Disease‐free – sourced from certified and fully traceable livestock
-
Culturally acceptable and Halal certified – there is no known cultural or religious group that objects to the use of ovine products
-
High purity and thermal stability – optimises function and reduces impurities
The company currently markets OVICOLL®|C and OVICOLL®|Clear for cosmetic applications and OVICOLL®|R for research applications. OVICOLL®|M for medical purposes is expected to be released in late 2008.
Enquiries:
Stephen Carter Alan Boys Non‐Executive Chairman Company Secretary P: +618 9426 3900 P: +618 9386 4003
CollTech Australia Ltd | ABN 24 094 515 992 PO Box 1661 Osborne Park WA 6916 Australia P +618 9426 3900 | F +618 9426 3909 | W www.colltech.com.au | E [email protected]
Enquiries:
==> picture [151 x 53] intentionally omitted <==
ASX/MEDIA RELEASE
Media: Sarah Allchurch P: +618 9381 6625 M: +61 412 346 412 E: [email protected]
CollTech Australia Ltd | ABN 24 094 515 992 PO Box 1661 Osborne Park WA 6916 Australia P +618 9426 3900 | F +618 9426 3909 | W www.colltech.com.au | E [email protected]